Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Taiko Gains on Japan’s Drug-Resistant Bacteria Cases

Sept. 7 (Bloomberg) -- Taiko Pharmaceutical Co., a Japanese maker of antiseptics, rose the most since listing on the Tokyo Stock Exchange after several types of drug-resistant bacteria were reportedly found in the country.

The stock surged 29 percent to 1,336 yen as of 1:26 p.m. on the exchange, the biggest gain since March 2009. Taiko has fallen 30 percent this year, compared with 7.8 percent decline in the benchmark Topix index.

Forty-six patients have been infected with a drug-resistant bacterium called Acinetobacter at Tokyo’s Teikyo University Hospital over the past year, the Yomiuri newspaper reported today. The report also said bacteria with the NDM-1 gene, resistant to almost all antibiotics, was identified for the first time in Japan yesterday in a patient at Dokkyo Medical University Hospital, north of Tokyo.

“The stock’s surge may be attributed to the new bacterium,” said Hitoshi Ohnishi, an analyst at Cosmo Securities Co., who has a “neutral plus” rating on Osaka-based Taiko. “I don’t know how effective their products are, but the company has an established reputation in the antibacterial business.”

To contact the reporter on this story: Masatsugu Horie in Osaka at mhorie3@bloomberg.net

To contact the editor responsible for this story: Drew Gibson at dgibson2@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.